SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Infinity Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (10)4/12/2006 1:49:40 PM
From: rkrw  Respond to of 210
 
Combined company market value of roughly $220M doesn't seem so low to me for a phase I company. Strong cash position but probably a high burn rate. I don't think they could have done better in an ipo today. Good for both companies shareholders. imo.

Given infi and mgt could be liable if there were a conspiracy to cover up something ominous, that idea seems far fetched. Probably no more risky or less risky than any other early stage bio out there. I think it is what it is, a nifty, easier and cheaper way to get public, get liquid and access public capital to build a company.



To: DewDiligence_on_SI who wrote (10)4/12/2006 1:50:53 PM
From: dr.praveen  Read Replies (1) | Respond to of 210
 
I was surprised it was DPII at first, but DPII is a better choice
because it is a public co with some cash, no overhangs like dpii drugs and debt.(In the case of predix merger with epix)

I can't see any dark clouds on its drug pipeline. I am sure they will be more PR from Infinity which will lift it's stock:-)

PS: Any plans to get in?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News